Toll-like receptor (TLR) gene expression and immunostimulatory effect of CpG oligonucleotides in hormone receptor positive cell line T47D and triple negative breast cancer cell line MDA-MB-468.

Immunopharmacology and Immunotoxicology
Sudhakar Natarajan, Mohan Ranganathan

Abstract

We investigated the expression of TLR genes and the effects of CpG ODN in Estrogen Receptor positive, Progesterone Receptor positive breast cancer cell line (T47D) and a triple-negative breast cancer cell line (MDA-MB-468) followed by studying the immunostimulatory activity of CpG oligonucleotides in breast cancer cell lines T47D and MDA-MB-468. We evaluated the expression pattern of TLR genes (TLR1 to TLR9) in T47D and MDA-MB-468 cells using Real-time qPCR analysis. The intracellular TLR9 protein expression was studied by flow cytometry. The effect of CpG ODN on cell viability was tested using MTT assay. The relative expression of pro-inflammatory (IL6 and TNFα) and anti- inflammatory/immunosuppressive cytokines genes (IL10 and TGF beta1) were examined by Real-time qPCR. We found that MDA-MB-468 cells expressed TLR2, TLR3, TLR6, TLR8, and TLR9 genes and T47D cells expressed TLR3, TRL5, TLR8, and TLR9 genes. Stimulation of TLR9 in vitro with CpG significantly reduced the cell viability of T47D and MDA-MB-468 cells. IL6 cytokine gene expression was significantly reduced in both CpG treated T47D cells and MDA-MB-468 cells. TNFα gene expression was significantly reduced after treatment with CpG in MDA-MB-468 cells but not in T47D ...Continue Reading

References

Apr 6, 1995·Nature·A M KriegD M Klinman
Dec 29, 2000·Nature·H HemmiS Akira
Jul 27, 2001·Proceedings of the National Academy of Sciences of the United States of America·S BauerG B Lipford
Feb 28, 2002·Annual Review of Immunology·Charles A Janeway, Ruslan Medzhitov
Oct 15, 2003·Clinical Microbiology Reviews·S Janssens, R Beyaert
Jan 31, 2004·Seminars in Immunology·Kiyoshi Takeda, Shizuo Akira
Jul 2, 2004·Nature Reviews. Immunology·Shizuo Akira, Kiyoshi Takeda
Feb 25, 2006·Cell·Shizuo AkiraOsamu Takeuchi
Mar 3, 2007·The Lancet Oncology·Susan CleatorR Charles Coombes
Jun 26, 2007·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·A Kate SasserBrett M Hall
Sep 12, 2007·Trends in Immunology·Anna Rubartelli, Michael T Lotze
Aug 18, 2009·Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society·Yusuke SatoDave S B Hoon
Jun 16, 2010·Current Drug Targets·Jodi E Goldberg, Kathryn L Schwertfeger
Jul 14, 2010·Journal of Experimental & Clinical Cancer Research : CR·Huan YangXueming Zhu
Sep 3, 2011·Breast Cancer Research : BCR·Deborah L Holliday, Valerie Speirs
Dec 25, 2012·International Journal of Molecular Sciences·Valentina PileczkiIoana Berindan-Neagoe
Feb 13, 2014·PloS One·Cendy A Valle Oseguera, Juliet V Spencer
Sep 24, 2015·Breast Cancer Research : BCR·Meliha MehmetiKarin Leandersson
Jul 10, 2016·Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society·Didier MeseureIvan Bieche
Jun 3, 2017·Human Vaccines & Immunotherapeutics·Sulsal Haque, John C Morris
Jun 1, 2018·Journal of Translational Medicine·Zehuan LiJin Wang

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.